Related by context. All words. (Click for frequent words.) 76 stage IIIB IV 73 metastatic colorectal 72 metastatic bladder 71 malignant pleural mesothelioma 71 Hepatocellular Carcinoma HCC 71 recurrent NSCLC 71 prostate carcinoma 71 squamous cell lung cancer 71 metastatic gastric 70 metastatic lung cancer 70 Pemetrexed 70 HER2 positive cancers 70 basal cell carcinoma BCC 70 Squamous 70 KRAS mutations occur 70 Lung transplantation 69 Zolinza 69 biliary tract cancer 69 pancreatic lung 69 pancreatic adenocarcinoma 69 non squamous 69 gastrointestinal stromal tumors 69 HNSCC 69 renal cell carcinomas 69 invasive ductal 69 gefitinib Iressa 69 relapsed MM 69 IV NSCLC 69 Surgical resection 69 differentiated thyroid 69 nonmetastatic 69 Chronic lymphocytic leukemia 69 K ras mutations 69 Medullary thyroid cancer 69 Nexavar sorafenib 69 unresectable tumors 69 serous ovarian cancer 68 recurrent glioblastoma multiforme 68 squamous histology 68 Metastatic breast cancer 68 renal carcinoma 68 Xelox 68 recurrent metastatic 68 neuroendocrine cancers 68 Velcade bortezomib 68 papillary renal cell carcinoma 68 MAGE A3 ASCI 68 gemcitabine carboplatin 68 pediatric acute lymphoblastic 68 PSMA ADC 68 Adjuvant chemotherapy 68 metastatic HER2 positive 68 stage IIIB 68 metastatic renal cell carcinoma 68 stage IIIb IV 68 Dacogen decitabine 68 recurrent glioblastoma multiforme GBM 68 lymphocytic leukemia 68 carcinoma HCC 68 leukemia AML 68 medically inoperable 68 hepatocellular carcinomas 68 nonmelanoma skin cancers 68 stage IIIA 68 ductal breast cancer 68 gemcitabine chemotherapy 68 Stage IIIb 68 ovarian breast 68 completely resected 67 pancreatic NET 67 peritoneal carcinomatosis 67 colorectal lung 67 cisplatin chemotherapy 67 concurrent chemoradiation 67 peritoneal cancer 67 sorafenib Nexavar 67 T1c 67 advanced medullary thyroid 67 GISTs 67 CYT# potent vascular disrupting 67 Amrubicin 67 Bayer HealthCare Onyx Pharmaceuticals 67 autoantibody positive 67 operable breast cancer 67 Gleevec imatinib mesylate 67 allogeneic HSCT 67 smoldering myeloma 67 Waldenstrom macroglobulinemia 67 MGd 67 breast pancreatic 67 Temsirolimus 67 chemotherapy cisplatin 67 nasopharyngeal carcinoma 67 medullary thyroid cancer 67 seminoma 67 unresectable stage 67 underwent surgical resection 67 ToGA 67 sorafenib tablets 67 non squamous NSCLC 67 EGFR mutation positive 67 iniparib 67 Gleevec resistant 67 preoperative chemotherapy 67 irinotecan chemotherapy 67 metastatic renal cell 67 metastatic RCC 67 metastatic kidney 67 invasive lobular 67 BRAF inhibitor 67 LHRH receptor positive 67 bladder cancers 67 myelofibrosis polycythemia vera 67 KRAS mutation 67 Folfox 67 Daclizumab 67 SCCHN 67 sarcomatoid 67 cediranib 67 myelofibrosis MF 67 liver metastases 67 NSCLC 67 malignant lymphoma 67 Basal cell 67 pegylated liposomal doxorubicin 67 YONDELIS 67 proteasome inhibitor 67 breast carcinomas 67 Chronic myeloid leukemia 67 ZACTIMA 67 HER2 amplified 66 PD LID 66 ErbB2 positive 66 carcinoid tumors 66 bronchogenic carcinoma 66 squamous non 66 gastrointestinal stromal tumors GISTs 66 lung adenocarcinomas 66 erlotinib Tarceva ® 66 EGFR mutation 66 Papillary 66 gastrointestinal stromal tumor 66 DCVax Brain 66 carcinoid 66 relapsing remitting MS RRMS 66 epithelial tumors 66 cilengitide 66 taxane chemotherapy 66 p# biomarker 66 colorectal carcinoma 66 breast carcinoma 66 malignant ascites 66 receptor tyrosine kinase inhibitor 66 colorectal breast 66 Glioblastoma Multiforme GBM 66 squamous cell carcinoma SCC 66 KRAS wild 66 renal cell carcinoma 66 Acute myeloid leukemia 66 neuroendocrine carcinoma 66 lenalidomide Revlimid R 66 corticosteroid dexamethasone 66 relapsed ovarian cancer 66 hepatorenal syndrome 66 Lilly Gemzar 66 antibody MAb 66 hepatocellular cancer 66 BR.# 66 Doxil ® 66 gastric carcinoma 66 metastatic malignant 66 ductal cancer 66 tumor xenograft models 66 orthotopic model 66 ER CHOP 66 pleural mesothelioma 66 tumors GIST 66 Allovectin 7 ® 66 cervical carcinoma 66 invasive candidiasis 66 liver metastasis 66 Aplidin 66 nonsquamous 66 BRCA deficient 66 mutated K ras 66 palliative radiotherapy 66 resected pancreatic cancer 66 kidney urologic 66 acute leukemias 66 docetaxel chemotherapy 66 trabectedin 66 metastatic malignant melanoma 66 MALT lymphoma 66 candidemia 66 anti angiogenic agents 66 cisplatin resistant 66 gastric adenocarcinoma 66 NSCLC tumors 66 docetaxel Taxotere ® 66 Renal Cell Carcinoma RCC 66 pancreatic carcinoma 65 colorectal adenoma 65 situ LCIS 65 standard chemotherapy regimens 65 refractory ovarian cancer 65 lobular carcinoma 65 grade cervical intraepithelial 65 Proxinium TM 65 hormone receptor negative 65 prostate cancer PCa 65 AA Amyloidosis 65 resistant hormone refractory 65 Glioblastoma multiforme GBM 65 myelodysplastic syndrome MDS 65 Pertuzumab 65 liposomal doxorubicin 65 humanised monoclonal antibody 65 chemotherapeutic regimen 65 cancer mCRC 65 acute myeloid 65 standard chemotherapy regimen 65 rituximab Rituxan 65 histologic subtype 65 alpha1 antitrypsin deficiency 65 Glioblastoma Multiforme 65 mycosis fungoides 65 lobular cancer 65 urothelial carcinoma 65 pertuzumab 65 lung metastases 65 refractory metastatic 65 thalidomide Thalomid 65 Proleukin 65 histologies 65 malignant neoplasm 65 HER2 overexpression 65 BRAF V#E mutation 65 chemoradiation therapy 65 HBeAg negative 65 bladder ovarian 65 systemic ALCL 65 GBM tumors 65 Allovectin 7 65 IV melanoma 65 chronic myeloid 65 pancreatic neuroendocrine tumors 65 nonmelanoma 65 oral clodronate 65 glioblastoma multiforme GBM 65 erlotinib Tarceva 65 Alemtuzumab 65 invasive lobular carcinoma 65 refractory metastatic colorectal cancer 65 eflornithine 65 Xanafide 65 pancreatic islet cell 65 INSPIRE Trial Phase III 65 OncoVex 65 NovoTTF 65 trastuzumab DM1 65 benign neoplasms 65 lung adenocarcinoma 65 endometrial hyperplasia 65 OncoVEX GM CSF 65 skeletal metastases 65 lung pancreatic 65 castrate resistant 65 PROSTVAC VF 65 Roche Herceptin 65 urothelial cancer 65 histological subtype 65 colorectal carcinomas 65 colorectal polyp 65 fallopian tube carcinoma 65 SCIg 65 neuroendocrine tumors 65 adenocarcinomas 65 Hurthle cell 65 pediatric malignancies 65 HER2 positive metastatic breast 65 locoregional 65 metachronous 65 BRIM2 65 miRview ™ squamous 65 platinum refractory 65 pT2 65 microtubule inhibitor 65 metastatic renal 65 advanced metastatic prostate 65 adjuvant radiotherapy 65 CTAP# Capsules 65 Genentech Rituxan 65 pancreatic neuroendocrine 65 superficial basal cell carcinoma 65 EGFR mutant 65 Aflibercept 65 mCRC patients 65 Uterine cancer 65 Trastuzumab DM1 64 cutaneous melanoma 64 nodal metastasis 64 EGFR blockers 64 subependymal giant cell 64 KRAS mutations 64 Degarelix 64 OvaRex ® MAb 64 dasatinib Sprycel 64 eribulin mesylate 64 epithelial ovarian 64 Hodgkin lymphoma HL 64 alveolar rhabdomyosarcoma 64 relapsed leukemia 64 lymphomas leukemias 64 sunitinib malate 64 efalizumab 64 lymphoid malignancies 64 Evoltra ® 64 gastrointestinal cancers 64 ixabepilone 64 lymphoid tumors 64 Chronic Myelogenous Leukemia CML 64 Tarceva erlotinib 64 metastatic colon cancer 64 geographic atrophy 64 endocrine therapies 64 mutated KRAS gene 64 locoregional recurrence 64 Crizotinib 64 KRAS mutant 64 Sutent sunitinib 64 advanced hepatocellular carcinoma 64 thymoma 64 metastatic medullary thyroid 64 metastatic lymph nodes 64 targeted radiotherapeutic 64 hematological malignancy 64 gastrointestinal stromal tumors GIST 64 ANCA associated 64 tigecycline 64 pemphigus vulgaris 64 ovarian carcinoma 64 Cabazitaxel 64 drug Treanda 64 axitinib 64 colorectal cancer liver metastases 64 imatinib Gleevec 64 follicular thyroid cancer 64 ImClone Erbitux 64 GVAX 64 epithelial ovarian cancer 64 neratinib 64 ano genital warts 64 HyperAcute 64 OHR/AVR# 64 Rituxan rituximab 64 deCODE ProstateCancer TM 64 neoadjuvant therapy 64 FOLFOX6 64 papillary carcinoma 64 Faslodex 64 docetaxel Taxotere 64 Vandetanib 64 paclitaxel Taxol ® 64 oral squamous cell 64 olaparib 64 postoperative chemotherapy 64 sorafenib Nexavar ® 64 untreated metastatic melanoma 64 ovarian pancreatic 64 prostate adenocarcinoma 64 recurrent glioblastoma 64 metastatic hormone refractory 64 Colon polyps 64 Cloretazine 64 ductal lobular 64 IV metastatic melanoma 64 prostate cancer CaP 64 ancrod 64 Ceflatonin 64 Glioblastoma multiforme 64 DCVax ® 64 ductal carcinomas 64 relapsed SCLC 64 taxane refractory 64 recurrent colorectal cancer 64 cetuximab Erbitux 64 PSADT 64 radiation chemoradiation 64 pancreatic prostate 64 Epithelial ovarian cancer 64 demonstrated antitumor activity 64 SIR Spheres 64 CIMZIA ™ 64 CTEPH 64 Atrasentan 64 ASCUS 64 IDH1 mutation 64 underwent resection 64 Canvaxin TM 64 gastrointestinal stromal tumor GIST 64 dacarbazine chemotherapy 64 invasive carcinomas 64 myeloproliferative disorders 64 ductal adenocarcinoma 64 acute myelogenous leukemia AML 64 KRAS oncogene 64 haematological cancers 64 HER2 expression 64 MYDICAR ® 64 ovarian prostate 64 Sudhir Agrawal D.Phil 64 advanced adenoma 64 neuroblastoma tumors 64 metastatic ovarian cancer 64 cytoreduction 64 galiximab 64 gadobutrol 64 Peginterferon alfa 2b 64 Vectibix panitumumab 64 PCNSL 64 Solazed 64 chronic HBV 64 superficial bladder cancer 64 chronic periodontitis 64 hA# 64 hepatic metastases 64 Jevtana 64 bendamustine 64 Tarceva TM 64 advanced adenomas 64 Zybrestat 64 diabetic kidney 64 TTF Therapy 64 flavopiridol 64 ZOLINZA 64 R sorafenib tablets 64 Squamous cell 64 bevacizumab Avastin 64 vismodegib 64 surgically resectable 64 5 fluorouracil leucovorin 64 multiple myeloma MM 64 ovarian endometrial 64 follicular lymphoma FL 64 prostate ovarian 63 Hycamtin 63 Chronic lymphocytic leukemia CLL 63 mucinous 63 FOLFIRI alone 63 YONDELIS R 63 metastatic pancreatic 63 oral ridaforolimus 63 myeloid leukemia 63 hepatoma 63 Advexin 63 complete cytogenetic response 63 ovarian lung 63 GRNCM1 63 Radical prostatectomy 63 intra arterial chemotherapy 63 GRNVAC1 63 low dose cytarabine 63 regorafenib 63 advanced epithelial ovarian 63 Acute Myeloid Leukaemia AML 63 precursor lesions 63 PROLARIS 63 osteosarcomas 63 chronic HCV 63 Interferon alfa 63 MabThera Rituxan 63 Vitaxin 63 ximelagatran 63 elacytarabine 63 metastatic adenocarcinoma 63 leukaemias 63 pilocytic astrocytomas 63 LRAT 63 bile duct cancers 63 bicalutamide 63 DCVax R 63 SUVmax 63 chemoradiotherapy 63 gastrointestinal malignancies 63 anastrazole 63 azacytidine 63 ADPKD 63 chemotherapeutic regimens 63 depsipeptide 63 MYCN amplification 63 mRCC 63 GIST tumors 63 androgen independent 63 Myelodysplastic Syndrome MDS 63 Naive Patients 63 transthyretin amyloidosis 63 Nilotinib 63 histologically confirmed 63 BrachySil TM 63 Bayer Nexavar 63 Herceptin trastuzumab 63 neoplasias 63 Gliadel Wafer 63 hematopoietic cancers 63 somatostatin analogues 63 Stage IIB 63 radiofrequency ablation RFA 63 antiangiogenic therapy 63 stage IIIb 63 metastatic carcinoma 63 myelogenous leukemia 63 Ontak 63 Temodar ® 63 Endometrial cancer 63 gallium nitrate 63 PNH patients 63 Epratuzumab 63 HER2 positive breast cancer 63 invasive ductal carcinoma 63 Neuvenge 63 PARP inhibitor 63 paclitaxel Taxol R 63 clinically localized prostate 63 squamous 63 haematologic 63 KRAS status 63 baseline LDH 63 Erbitux cetuximab 63 Torisel 63 including eniluracil ADH 63 mutated KRAS 63 sargramostim 63 bowel cancers 63 temsirolimus 63 adenomatous 63 Vicinium TM 63 Ixempra 63 leukemia ALL 63 leukemia multiple myeloma 63 CIN3 63 brivanib 63 paricalcitol 63 refractory chronic myeloid 63 Renal cell carcinoma 63 trastuzumab DM1 T DM1 63 intraductal 63 renal tumors 63 Bezielle 63 Bevacizumab Avastin 63 efaproxiral 63 AVOREN 63 farletuzumab 63 T#I [002] 63 HQK 63 testicular cancers 63 colorectal liver metastases 63 hematologic disorders 63 pain palliation 63 Xcellerated T Cells 63 midstage clinical 63 trastuzumab Herceptin R 63 calcineurin inhibitor 63 metastatic GIST 63 enzastaurin 63 lung cancer NSCLC 63 Tarvacin 63 squamous cell 63 Omacetaxine 63 adriamycin 63 Pegintron 63 squamous cell cancers 63 basal cell skin 63 Deforolimus 63 castration resistant 63 decompensated liver disease 63 HGPIN 63 Arranon 63 leukemias lymphomas 63 metastatic neuroendocrine tumors 63 metastatic lesions 63 Virulizin ® 63 Tykerb lapatinib 63 Vidaza azacitidine 63 anti angiogenic therapy 63 samalizumab 63 hepatitis C HCV 63 Riluzole 63 AEG# 63 oral Hycamtin 63 PhG alpha 1 63 aflibercept VEGF Trap 63 hepatocellular carcinoma HCC 63 lymph node metastases 63 essential thrombocythemia ET 63 lupus nephritis 63 esophageal gastric 63 HER2 positivity 63 HIV HCV coinfected 63 resectable 63 gamma secretase inhibitor 63 colorectal cancer CRC 63 sunitinib Sutent 63 gastric cancers 63 stereotactic radiotherapy 63 chronic lymphocytic leukemia CLL 63 IMA# 63 EndoTAG 63 LBH# 63 histone deacetylase HDAC inhibitor 63 Hycamtin ® 63 refractory prostate cancer 63 MAGE A3 63 bortezomib Velcade 63 EOquin TM phase 63 temozolomide Temodar 63 myelodysplastic syndromes 63 Non Hodgkins lymphoma 63 radiochemotherapy 63 pheochromocytoma 63 pulmonary metastases 63 bevacizumab Avastin ® 63 HER2 amplification 63 TTR amyloidosis 63 INCB# [003] 63 Azedra 63 relapsed multiple myeloma 63 TEMODAL 63 GRNOPC1 contains 63 Taxotere docetaxel 63 parathyroid carcinoma 63 AML acute myeloid 63 pT3 63 neovascular 63 diffuse gastric 63 untreated metastatic colorectal 63 Camptosar ® 63 Quinamed 63 GSTP1 63 CIN2 + 63 Arsenic trioxide 63 bladder tumors 63 nucleotide analogue 63 IV bisphosphonates 63 elevated LDH 63 chromosomal mutations 63 malignant pleural mesothelioma MPM 63 IV malignant melanoma 63 hepatocellular carcinoma 63 taxane therapy 63 allogeneic bone marrow 63 MGUS 63 Oncotype 63 tumor histology 63 tolevamer 63 unresectable liver cancer 63 unresectable 63 EndoTAGTM 1 63 goserelin 63 lung tumors 63 figitumumab 63 luteinizing hormone releasing 63 Irinotecan 63 adjuvant cisplatin 63 GW# [003] 63 Her2/neu 63 atypical hyperplasia 63 gemcitabine Gemzar 63 thetreatment 63 premalignant lesion 63 dacarbazine DTIC 63 symptomatic BPH 63 chemoresistant 63 Leukemias 63 FluCAM arm 63 docetaxel Taxotere R 63 Phase #b/#a clinical 63 mitoxantrone plus 62 thoracoscopic lobectomy 62 Thalomid ® 62 breast cancer subtypes 62 fluoropyrimidine 62 Gemzar ® 62 Mitomycin C 62 Certican 62 Gastric cancer 62 placebo dexamethasone 62 BRIM3 62 Seliciclib 62 mesotheliomas 62 latent celiac disease 62 localized renal 62 Kit CD# positive 62 cytokine refractory 62 prostate carcinomas 62 capecitabine Xeloda R 62 endometrioid 62 huC# DM4 62 gemcitabine cisplatin 62 ADAMTS# 62 Onco TCS 62 Certolizumab pegol 62 Fludara ® 62 metastatic HRPC 62 Onrigin 62 Mipomersen 62 CLL SLL 62 metastatic basal cell 62 HuMax EGFr 62 oligodendrogliomas 62 Afatinib 62 secondary hyperparathyroidism 62 refractory chronic lymphocytic 62 lymphoma subtypes 62 thymalfasin 62 cytotoxic therapy 62 Glaxo Tykerb 62 castration resistant prostate cancer 62 eribulin 62 non metastatic osteosarcoma 62 Her2 positive 62 Canvaxin 62 OnDose TM 62 midstage clinical trials 62 Haptoglobin 62 basal cell nevus syndrome 62 RAS mutations 62 syngeneic 62 idraparinux 62 smoldering multiple myeloma 62 chemoembolization 62 abacavir Ziagen 62 Gemzar gemcitabine 62 histological subtypes 62 untreated AML 62 curative resection 62 polycythemia vera PV 62 invasive carcinoma 62 HER2 receptor 62 gene BRCA2 62 Ceplene/IL-2 62 imatinib Gleevec ® 62 volociximab 62 Kahalalide F 62 BRAF V# mutation 62 colon lung 62 metastatic breast 62 recurrent malignant glioma 62 Platinol ® cisplatin 62 sentinel lymph node biopsy 62 AKT inhibitor 62 immunodeficiency disorders 62 cutaneous T 62 evaluating tivozanib 62 hormone refractory metastatic prostate 62 EGFR tyrosine kinase inhibitors 62 IL# PE#QQR 62 pelvic malignancies 62 EOquin TM 62 Cervista HPV HR 62 Alessandro Riva 62 mertansine 62 Oncophage vitespen 62 prostate cancer CRPC 62 metastatic prostate cancer 62 Campath alemtuzumab 62 Phase IIb clinical trials 62 vinca alkaloid 62 localized prostate 62 antimetabolite 62 GRN# 62 BEXXAR Therapeutic Regimen 62 macroalbuminuria 62 Tavocept 62 INCB# [001] 62 papillary RCC 62 phase IIb study 62 precancers 62 fallopian tube cancers 62 Paraplatin ® carboplatin 62 moderately emetogenic 62 Axitinib 62 basiliximab 62 Leukine ® 62 carboplatin paclitaxel 62 AGHD 62 radiation sensitizer 62 mTOR inhibitor 62 essential thrombocythemia 62 extracapsular extension 62 anthracycline taxane 62 Follicular Lymphoma 62 colorectal neoplasms 62 methylation markers 62 TRAIL R1 62 Eli Lilly Gemzar 62 ependymoma 62 cyclophosphamide chemotherapy 62 multicenter Phase II 62 hepatocellular carcinoma liver 62 relapsed ALL 62 alvespimycin 62 metaglidasen 62 Azacitidine 62 BRCA1 BRCA2 62 vemurafenib 62 cervical lymph nodes 62 Recombinant interferon alpha 62 ara C 62 LHRH agonists 62 hypereosinophilic syndrome 62 cholangiocarcinoma 62 refractory AML 62 Anaplastic 62 5-FU/LV 62 Genasense ® 62 commercialize deforolimus 62 refractory multiple myeloma 62 Alkeran 62 Erlotinib 62 fibrate drugs 62 trastuzumab Herceptin ® 62 Glivec imatinib 62 recurrent squamous cell carcinoma 62 Sezary syndrome 62 radioiodine therapy 62 vinca alkaloids 62 Glioma 62 PAOD 62 node metastases 62 Neo Bladder Augment 62 metaplasia 62 distant metastasis 62 Dasatinib 62 phase IIb clinical 62 common hematologic malignancy 62 Rectal cancer 62 sipuleucel T 62 acyclovir Lauriad R 62 Metastatic colorectal cancer 62 Rilonacept 62 lapatinib Tykerb 62 contralateral breast 62 Endometrial 62 5alpha reductase 62 indolent lymphomas 62 pegylated interferon alpha 62 PROSTVAC TM 62 DEB# 62 invasive ductal breast cancer 62 Malignant Melanoma 62 angiogenesis inhibitor 62 EUS FNA 62 teriflunomide 62 Lodamin 62 molecular abnormalities 62 paclitaxel Taxol 62 monocytic 62 gastrin analogue TT 62 prostate cancer HRPC 62 premalignant 62 adult chronic ITP 62 virotherapy 62 cinacalcet 62 ELOXATIN 62 elevated triglyceride levels 62 lung metastasis 62 adecatumumab 62 Neulasta ® 62 PegIntron 62 untreated metastatic pancreatic 62 RhuDex R 62 Nexavar tablets 62 forodesine 62 LungAlert TM 62 intra abdominal abscess 62 taxane resistant 62 anticancer therapy 62 T1a 62 interferon gamma 1b 62 benign prostatic hypertrophy BPH 62 K ras gene 62 endostatin 62 Tesmilifene 62 CYPHER Stent 62 TNF antagonist 62 ospemifene 62 GORE TAG Device 62 distinct subtypes 62 FDG PET imaging 62 inhibitor RG# 62 postoperative pathology 62 iniparib BSI 62 Pfizer Sutent 62 metastatic castration resistant 62 AA amyloidosis 62 indibulin 62 AML MDS 62 soft tissue sarcomas 62 tamoxifen Nolvadex ® 62 Monoclonal antibody 62 Novartis Zometa 62 grade gliomas 62 mTOR inhibitors 62 FLT3 mutations 62 HCV infections 62 thymic carcinoma 62 Carcinoid tumors 62 unresectable locally advanced 62 gastric cancer 62 daunorubicin 62 cervical lymph node 62 zalutumumab 62 indolent follicular non 62 radezolid 62 lung esophageal 62 haematologic malignancies 62 fluvastatin 62 tyrosine kinase inhibitors TKIs 62 exemestane Aromasin 62 doublet chemotherapy 62 ALK inhibitors 62 A1PI 62 JAK inhibitors 62 BCIRG 62 Epstein Barr virus EBV 62 Halaven 62 budesonide foam 62 intravesical therapy 62 minimally symptomatic 62 aflibercept 62 cell carcinomas 62 Lilly Alimta 62 oesophageal adenocarcinoma 62 etanercept Enbrel 62 colorectal liver 62 Vidaza ® 62 Zavesca R 62 rheumatoid arthritis psoriatic arthritis 62 metastatic castrate resistant 62 anti EGFR antibody 62 Enzastaurin 62 Shark cartilage 62 biologic DMARD 62 Revlimid lenalidomide 62 gastrointestinal stromal 62 anaplastic 62 systolic dysfunction 62 TG# [003] 62 BAY #-# 62 nutlin 3a 62 SHPT 62 malignant pheochromocytoma 62 Myelodysplastic syndromes MDS 62 LymphoStat B belimumab 62 non mutated KRAS 62 Syncria 61 small lymphocytic lymphoma 61 liposomal formulation 61 nasopharyngeal cancer 61 FOLFOX chemotherapy 61 Cholangiocarcinoma 61 axillary dissection 61 CCR5 receptor antagonist 61 Genentech Herceptin 61 intrahepatic bile duct 61 pan HDAC inhibitor 61 pancreatic cancers 61 Panzem 61 ZACTIMA TM ZD# 61 Fluorouracil 61 adjuvant radiation 61 indolent NHL 61 androgen receptor antagonist 61 PARP inhibition 61 octreotide LAR 61 Epoetin alfa 61 recurrent GBM 61 HGS ETR1 61 intratumoral injection 61 pilocytic astrocytoma 61 huN# DM1 61 monoclonal antibody conjugated 61 GRASPA ® 61 acetonide FA 61 Tumors shrank 61 precancerous cervical 61 acute STEMI 61 Avastin bevacizumab 61 recurrent VTE 61 RhuDex ® 61 cabazitaxel 61 Ribavirin causes 61 grade cervical dysplasia 61 LEUKINE 61 follicular lymphomas 61 BARACLUDE ® 61 GnRH agonists 61 PARP inhibitors 61 CDDO Im